MiNK Therapeutics IncINKT
Price$12.73

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$11.4MTTM through 30 Jun 2026
Free Cash Flow -$6.8MTTM through 30 Jun 2026

Margins

Current

Returns

81.0%ROE
-118.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio1.23x
Net Debt-$9.5Mnet cash position
Cash & Equivalents$8.8M

Quality Metrics

Altman Z-Score-26.00
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$2.37TTM
'21'22'23'24'25
FY2025: $-2.93

Dividend

No dividend

Capital Allocation

R&D Spend$5.7M

Segment Performance

SegmentRevenueYoYOutlook
Allogeneic iNKT Cell Therapies$0
View details

Initiated randomized Phase 2 trial of agenT-797 with preliminary data expected in the second half of 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.